Literature DB >> 9769151

BG-1 ovarian cell line: an alternative model for examining estrogen-dependent growth in vitro.

W S Baldwin1, S W Curtis, C A Cauthen, J I Risinger, K S Korach, J C Barrett.   

Abstract

Examination of estrogen-responsive processes in cell culture is used to investigate hormonal influence on cancer cell growth and gene expression. Most experimental studies have used breast cancer cell lines, in particular MCF7 cells, to investigate estrogen responsiveness. In this study we examined an ovarian cancer cell line, BG-1, which is highly estrogen-responsive in vitro. This observation, plus the fact that the cells are of ovarian rather than mammary gland origin, makes it an attractive alternative model. 17Beta-estradiol, epidermal growth factor, and insulin-like growth factorinduced proliferation of BG-1 and MCF7 cells. Viability was dependent on these growth factors in BG-1 cells, but not in MCF7 cells. Therefore, we examined the differences between these two cell lines with respect to estrogen and growth factor receptors. BG-1 cells have twice as many estrogen receptors as MCF7 cells, and BG-1 cells have higher insulin-like growth factor-1 and epidermal growth factor receptor levels than MCF7 cells. This may also explain why BG-1 cells proliferate 56% more robustly in serum and show more serum dependence in culture. In both BG-1 and MCF7 cells, epidermal growth factor receptor number is low (<20000/cell), while insulin-like growth factor-1 receptor level was highest in estrogen receptor positive cell lines. For example, insulin-like growth factor-1 receptor was higher in BG-1 and MCF7 cells than in estrogen receptor negative cells (HeLa > MDA-MB-435 > HBL100). In conclusion, BG-1 cells are an excellent model for understanding hormone responsiveness in ovarian tissue and an alternative for examining estrogen receptor-mediated and insulin-like growth factor-1/epidermal growth factor/estrogen cross-talk processes because of their sensitivity to these factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9769151     DOI: 10.1007/s11626-996-0015-9

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  25 in total

1.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.

Authors:  K K Steinberg; S B Thacker; S J Smith; D F Stroup; M M Zack; W D Flanders; R L Berkelman
Journal:  JAMA       Date:  1991-04-17       Impact factor: 56.272

2.  Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors.

Authors:  K R Geisinger; T E Kute; M J Pettenati; C E Welander; Y Dennard; L A Collins; M E Berens
Journal:  Cancer       Date:  1989-01-15       Impact factor: 6.860

3.  Estrogen action in the mouse uterus: characterization of the cytosol and nuclear receptor systems.

Authors:  K S Korach
Journal:  Endocrinology       Date:  1979-05       Impact factor: 4.736

Review 4.  Maturation of ovarian follicles: actions and interactions of pituitary and ovarian hormones on follicular cell differentiation.

Authors:  J S Richards
Journal:  Physiol Rev       Date:  1980-01       Impact factor: 37.312

5.  Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis.

Authors:  R D Zhang; I J Fidler; J E Price
Journal:  Invasion Metastasis       Date:  1991

6.  Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells.

Authors:  G M Clinton; C Rougeot; J Derancourt; P Roger; A Defrenne; S Godyna; W S Argraves; H Rochefort
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

7.  The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone.

Authors:  I J Laidlaw; R B Clarke; A Howell; A W Owen; C S Potten; E Anderson
Journal:  Endocrinology       Date:  1995-01       Impact factor: 4.736

8.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

9.  Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol.

Authors:  D M Ignar-Trowbridge; M Pimentel; M G Parker; J A McLachlan; K S Korach
Journal:  Endocrinology       Date:  1996-05       Impact factor: 4.736

10.  Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor.

Authors:  L Long; R Rubin; R Baserga; P Brodt
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

View more
  11 in total

1.  Vitamin D suppresses leptin stimulation of cancer growth through microRNA.

Authors:  Ravi Kasiappan; Yuefeng Sun; Panida Lungchukiet; Waise Quarni; Xiaohong Zhang; Wenlong Bai
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

2.  Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.

Authors:  Andrea Schröpfer; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Sonja Feix; Jelena Anacker
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

3.  Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

Authors:  Danielle Vicus; Barry Rosen; Jan Lubinski; Susan Domchek; Noah D Kauff; Henry T Lynch; Claudine Isaacs; Nadine Tung; Ping Sun; Steven A Narod
Journal:  Gynecol Oncol       Date:  2009-07-03       Impact factor: 5.482

4.  Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights.

Authors:  Elaine M Hurt; Jessica N Saykally; Bynthia M Anose; Kimberly R Kalli; Michel M Sanders
Journal:  Mol Cell Biochem       Date:  2008-07-12       Impact factor: 3.396

5.  Conditionally immortal ovarian cell lines for investigating the influence of ovarian stroma on the estrogen sensitivity and tumorigenicity of ovarian surface epithelial cells.

Authors:  Feng Jiang; Beatriz O Saunders; Edward Haller; Sandra Livingston; Santo V Nicosia; Wenlong Bai
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

6.  [Constitutive expression of the potential stem cell marker CD44 in permanent HNSCC cell lines].

Authors:  R Pries; N Wittkopf; K Hasselbacher; B Wollenberg
Journal:  HNO       Date:  2008-04       Impact factor: 1.284

7.  A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells.

Authors:  Chengjian Mao; Nicole M Patterson; Milu T Cherian; Irene O Aninye; Chen Zhang; Jamie Bonéy Montoya; Jingwei Cheng; Karson S Putt; Paul J Hergenrother; Elizabeth M Wilson; Ann M Nardulli; Steven K Nordeen; David J Shapiro
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

8.  Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer.

Authors:  Carine Bossard; Muriel Busson; David Vindrieux; Françoise Gaudin; Véronique Machelon; Madly Brigitte; Carine Jacquard; Arnaud Pillon; Patrick Balaguer; Karl Balabanian; Gwendal Lazennec
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

9.  Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.

Authors:  L A Annab; R E Hawkins; G Solomon; J C Barrett; C A Afshari
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

10.  Novel MicroRNA Reporter Uncovers Repression of Let-7 by GSK-3β.

Authors:  Rong Guo; Kotb Abdelmohsen; Patrice J Morin; Myriam Gorospe
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.